Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Cost - Minimization Analysis Of Treprostinil Vs. Epoprostenol As An Alternate To Oral Therapy: Non - Responders For The Treatment Of Pulmonary Arterial Hypertension, Lutchmie Narine, L. Hague, J. Walker, C. Vicente
Cost - Minimization Analysis Of Treprostinil Vs. Epoprostenol As An Alternate To Oral Therapy: Non - Responders For The Treatment Of Pulmonary Arterial Hypertension, Lutchmie Narine, L. Hague, J. Walker, C. Vicente
Lutchmie Narine
Idiopathic pulmonary arterial hypertension (IPAH) is associated with substantial morbidity and mortality. Treprostinil was compared to epoprostenol for the economic impact of treating IPAH patients who failed or were not candidates for bosentan. METHODS: The model was a cost-minimization analysis, assuming clinical equivalence was achieved by proper dosing of both drugs, in terms of survival and surrogate measures. Two theoretical cohorts of 270 patients were treated with subcutaneous treprostinil and intravenous epoprostenol, and were evaluated over 3 years using a spreadsheet model. Annual survival rates were estimated for the cohorts so that at endpoint 114 (42%) patients survived in both …